Hospital
Providence Health & Services Washington
Providence Health & Services Washington was paid $40.36M by Medicaid between Jan 2018 and Dec 2024, across 391 billing codes. Its largest line is J9271, Injection, pembrolizumab, 1 mg — 12% of everything it billed.
33Billing provider infoPROVIDENCE HEALTH & SERVICES WASHINGTON
CENTRALIA, WA 98531
CENTRALIA, WA 98531
33aNPI1376624981assigned 10/18/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$40.36M
24GClaims1,335,801
24DCodes billed391
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Washington
Rank by total paid#16 of 49
Median peer was paid$20.06M
This provider vs. median2.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official ANDERSON, DONALD controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 233,821 | $6.88M | |
| 2019 | 236,664 | $6.47M | |
| 2020 | 209,301 | $5.96M | |
| 2021 | 221,844 | $5.89M | |
| 2022 | 186,496 | $6.07M | |
| 2023 | 138,172 | $4.62M | |
| 2024incomplete | 109,503 | $4.48M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | 12% | 1,165 | 920 | $5.02M |
| 96361 | Intravenous infusion, hydration; each additional hour | 11% | 14,291 | 11,919 | $4.31M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 8.0% | 29,601 | 28,123 | $3.24M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 6.3% | 27,909 | 26,071 | $2.53M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.4% | 25,690 | 23,540 | $2.18M |
| 59025 | Fetal non-stress test | 4.9% | 12,122 | 4,333 | $1.96M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.7% | 9,503 | 9,195 | $1.51M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 3.7% | 12,029 | 9,257 | $1.48M |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 3.1% | 11,042 | 6,584 | $1.25M |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 2.3% | 4,242 | 3,177 | $911K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.2% | 7,117 | 6,755 | $868K |
| 96415 | 1.7% | 2,834 | 2,086 | $685K |
379 more codes
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.4% | 3,534 | $578K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.4% | 5,186 | $570K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.4% | 11,372 | $565K |
| 78815 | Positron emission tomography (PET) for limited area imaging | 1.2% | 1,106 | $503K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.2% | 11,289 | $482K |
| 77412 | 1.2% | 997 | $480K | |
| 76830 | Ultrasound, transvaginal | 1.0% | 4,816 | $418K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | 1.0% | 4,552 | $417K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.0% | 5,079 | $405K |
| 80053 | Comprehensive metabolic panel | <1% | 75,948 | $395K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 13,765 | $359K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 2,384 | $355K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 7,905 | $353K |
| J2505 | Injection, pegfilgrastim, 6 mg | <1% | 203 | $296K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,257 | $276K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,877 | $237K |
| 96523 | <1% | 4,463 | $233K | |
| 87631 | <1% | 7,225 | $230K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 5,495 | $229K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 3,155 | $224K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 3,028 | $206K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 460 | $202K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 2,810 | $198K |
| 12001 | <1% | 884 | $197K | |
| J9355 | Injection, trastuzumab, excludes biosimilar, 10 mg | <1% | 211 | $191K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 516 | $182K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 3,048 | $176K |
| 76801 | <1% | 2,775 | $169K | |
| 93971 | <1% | 1,788 | $161K | |
| 77336 | <1% | 2,741 | $150K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 17,457 | $139K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 87,876 | $138K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 3,053 | $128K |
| J0185 | Injection, aprepitant, 1 mg | <1% | 1,374 | $122K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 2,556 | $122K |
| 76642 | <1% | 1,572 | $122K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 56,285 | $119K |
| J0897 | Injection, denosumab, 1 mg | <1% | 366 | $107K |
| 84484 | <1% | 20,376 | $106K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 263 | $104K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 6,267 | $98K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 4,559 | $89K |
| 93017 | <1% | 735 | $89K | |
| 76770 | <1% | 954 | $88K | |
| 71250 | <1% | 1,908 | $86K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 564 | $83K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 273 | $77K |
| 74018 | <1% | 2,684 | $72K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 2,970 | $71K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 696 | $71K |
| 77334 | <1% | 486 | $57K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 930 | $55K |
| G0378 | Hospital observation service, per hour | <1% | 14,915 | $55K |
| 12002 | <1% | 262 | $53K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 10,235 | $53K |
| 10061 | <1% | 256 | $52K | |
| 73610 | <1% | 3,286 | $52K | |
| 83605 | <1% | 7,799 | $50K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 9,656 | $48K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 6,981 | $47K |
| 87400 | <1% | 3,250 | $46K | |
| 73630 | <1% | 3,168 | $46K | |
| 73130 | <1% | 2,958 | $42K | |
| 73110 | <1% | 2,292 | $41K | |
| 87040 | <1% | 5,884 | $41K | |
| 72100 | <1% | 2,278 | $41K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 1,734 | $40K |
| 73030 | <1% | 2,910 | $40K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 24,163 | $39K |
| 73562 | <1% | 2,305 | $39K | |
| 76536 | <1% | 419 | $39K | |
| 70496 | <1% | 363 | $38K | |
| 90715 | <1% | 2,196 | $38K | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 313 | $38K |
| 70498 | <1% | 543 | $38K | |
| 36591 | <1% | 2,656 | $37K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,115 | $35K |
| 86780 | <1% | 2,674 | $35K | |
| 97162 | <1% | 1,161 | $34K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 12,724 | $33K |
| 71271 | <1% | 417 | $33K | |
| 12011 | <1% | 120 | $31K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 163 | $30K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 6,267 | $30K |
| J9035 | Injection, bevacizumab, 10 mg | <1% | 26 | $30K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 478 | $29K |
| 84702 | <1% | 4,269 | $29K | |
| 77290 | <1% | 115 | $29K | |
| 84145 | <1% | 3,110 | $28K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,434 | $27K |
| 83880 | <1% | 5,543 | $27K | |
| 96367 | <1% | 2,521 | $26K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 963 | $26K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 3,116 | $26K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 20,518 | $25K |
| 80050 | General health panel | <1% | 3,200 | $25K |
| 73140 | <1% | 1,342 | $25K | |
| 97166 | <1% | 740 | $24K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 8,844 | $24K |
| 73502 | <1% | 1,756 | $24K | |
| 82728 | <1% | 4,414 | $24K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 21,701 | $23K |
| 85379 | <1% | 3,751 | $22K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,551 | $22K |
| 94770 | <1% | 265 | $22K | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 113 | $22K |
| 76882 | <1% | 272 | $22K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 116 | $21K |
| 86803 | <1% | 2,913 | $21K | |
| 10060 | <1% | 93 | $21K | |
| 87653 | <1% | 1,308 | $21K | |
| 80061 | Lipid panel | <1% | 2,984 | $20K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,141 | $20K |
| 70491 | <1% | 285 | $20K | |
| 76870 | <1% | 198 | $18K | |
| 86900 | <1% | 6,322 | $17K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 2,908 | $17K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,923 | $17K |
| 86850 | <1% | 5,916 | $17K | |
| 84439 | <1% | 3,366 | $16K | |
| 77300 | <1% | 234 | $16K | |
| 77066 | Tomosynthesis, mammo | <1% | 590 | $16K |
| 72040 | <1% | 1,101 | $16K | |
| 70486 | <1% | 407 | $16K | |
| 87420 | <1% | 1,065 | $16K | |
| 82607 | <1% | 2,134 | $15K | |
| 58558 | <1% | 15 | $15K | |
| 87210 | <1% | 4,275 | $15K | |
| 85055 | <1% | 3,012 | $14K | |
| 85027 | <1% | 6,183 | $14K | |
| 37799 | <1% | 217 | $13K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 30 | $13K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 260 | $13K |
| 87070 | <1% | 4,555 | $13K | |
| 84466 | <1% | 3,802 | $13K | |
| 93970 | <1% | 126 | $11K | |
| 99195 | <1% | 241 | $11K | |
| 87340 | <1% | 3,367 | $11K | |
| 83735 | <1% | 9,070 | $11K | |
| 73090 | <1% | 898 | $11K | |
| 83540 | <1% | 4,137 | $11K | |
| 82731 | <1% | 601 | $10K | |
| 73590 | <1% | 1,068 | $10K | |
| 73080 | <1% | 864 | $10K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,371 | $10K |
| 86140 | <1% | 3,860 | $9K | |
| 82378 | <1% | 1,562 | $9K | |
| 86901 | <1% | 6,313 | $9K | |
| 72110 | <1% | 294 | $9K | |
| 82950 | <1% | 2,413 | $8K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 700 | $8K |
| 73560 | <1% | 684 | $8K | |
| 85652 | <1% | 3,380 | $7K | |
| 87205 | <1% | 4,749 | $7K | |
| 71045 | Radiologic examination, chest; single view | <1% | 8,225 | $7K |
| 70470 | <1% | 78 | $7K | |
| 86762 | <1% | 2,077 | $7K | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 62 | $7K |
| 72141 | <1% | 43 | $7K | |
| J1447 | Injection, tbo-filgrastim, 1 microgram | <1% | 46 | $6K |
| 82962 | <1% | 16,661 | $6K | |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | <1% | 29 | $6K |
| 73564 | <1% | 103 | $6K | |
| 96368 | <1% | 1,446 | $6K | |
| 96376 | <1% | 4,716 | $6K | |
| 96402 | <1% | 725 | $5K | |
| 87186 | <1% | 3,751 | $5K | |
| 81001 | <1% | 26,821 | $5K | |
| 87640 | <1% | 425 | $5K | |
| 74174 | <1% | 25 | $5K | |
| 97116 | <1% | 352 | $5K | |
| 36430 | <1% | 45 | $5K | |
| 83690 | <1% | 13,574 | $5K | |
| 84112 | <1% | 553 | $5K | |
| 20610 | <1% | 29 | $5K | |
| 99292 | <1% | 233 | $5K | |
| 72072 | <1% | 238 | $5K | |
| 82746 | <1% | 1,262 | $5K | |
| 83615 | <1% | 3,014 | $5K | |
| 64483 | <1% | 13 | $4K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 902 | $4K |
| 85610 | <1% | 11,181 | $4K | |
| 82105 | <1% | 378 | $4K | |
| 86300 | <1% | 333 | $4K | |
| 87081 | <1% | 1,593 | $4K | |
| 82570 | <1% | 1,427 | $4K | |
| 82784 | <1% | 472 | $3K | |
| 92523 | <1% | 27 | $3K | |
| 77065 | Tomosynthesis, mammo | <1% | 124 | $3K |
| 94726 | <1% | 83 | $3K | |
| 87077 | <1% | 3,217 | $3K | |
| 84403 | <1% | 224 | $3K | |
| 84156 | <1% | 1,208 | $3K | |
| 29125 | <1% | 12 | $3K | |
| 87176 | <1% | 882 | $3K | |
| 83883 | <1% | 403 | $3K | |
| 87641 | <1% | 427 | $3K | |
| 83001 | <1% | 167 | $2K | |
| 84100 | <1% | 2,326 | $2K | |
| 84165 | <1% | 482 | $2K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,099 | $2K |
| 82565 | <1% | 1,004 | $2K | |
| 97161 | <1% | 66 | $2K | |
| J3489 | Injection, zoledronic acid, 1 mg | <1% | 85 | $2K |
| 81025 | <1% | 12,420 | $2K | |
| 82247 | <1% | 240 | $2K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 124 | $2K |
| 77080 | <1% | 36 | $2K | |
| 82951 | <1% | 218 | $2K | |
| J3490 | Unclassified drugs | <1% | 1,299 | $2K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 14,869 | $2K |
| 94729 | <1% | 86 | $2K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,582 | $2K |
| 86304 | <1% | 197 | $2K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 18,152 | $2K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 161 | $2K |
| 36592 | <1% | 478 | $2K | |
| J2997 | Injection, alteplase recombinant, 1 mg | <1% | 48 | $2K |
| 86706 | <1% | 815 | $2K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,828 | $2K |
| 87486 | <1% | 93 | $1K | |
| 72131 | <1% | 28 | $1K | |
| 97750 | <1% | 69 | $1K | |
| 92558 | <1% | 12 | $1K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 16,014 | $1K |
| 86704 | <1% | 770 | $1K | |
| 82805 | <1% | 4,398 | $1K | |
| 84146 | <1% | 94 | $1K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 9,069 | $1K |
| 82550 | <1% | 1,266 | $1K | |
| 74022 | <1% | 247 | $1K | |
| 74019 | <1% | 119 | $1K | |
| 87522 | Neg quan hep c or qual rna | <1% | 80 | $1K |
| 87147 | <1% | 1,527 | $1K | |
| 81003 | <1% | 2,853 | $1K | |
| 82248 | <1% | 285 | $960.83 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 110 | $948.51 |
| 84703 | <1% | 2,970 | $944.05 | |
| 85730 | <1% | 1,486 | $911.33 | |
| 94060 | <1% | 28 | $906.71 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 7,789 | $899.21 |
| 84155 | <1% | 520 | $874.29 | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 1,254 | $849.03 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 15,520 | $824.90 |
| 80164 | <1% | 81 | $814.32 | |
| 73700 | <1% | 13 | $780.16 | |
| 87581 | <1% | 93 | $757.90 | |
| 73660 | <1% | 28 | $756.62 | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 3,341 | $747.18 |
| J2704 | Injection, propofol, 10 mg | <1% | 6,591 | $735.24 |
| 84153 | <1% | 204 | $719.48 | |
| 84550 | <1% | 607 | $696.25 | |
| 92522 | <1% | 13 | $694.47 | |
| 86592 | <1% | 122 | $668.44 | |
| 87109 | <1% | 47 | $644.24 | |
| 93225 | <1% | 15 | $643.44 | |
| A9270 | Non-covered item or service | <1% | 18,606 | $640.86 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 11,009 | $625.13 |
| 87088 | <1% | 232 | $614.74 | |
| 97163 | <1% | 28 | $555.36 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 6,337 | $552.84 |
| 86141 | <1% | 389 | $532.21 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 14 | $529.76 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 6,007 | $516.27 |
| 93016 | <1% | 50 | $492.59 | |
| J2310 | Injection, naloxone hydrochloride, per 1 mg | <1% | 17 | $461.36 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 3,973 | $455.95 |
| 83970 | <1% | 18 | $448.88 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 6,164 | $431.35 |
| 90686 | <1% | 50 | $422.44 | |
| 88307 | <1% | 28 | $393.13 | |
| 80076 | <1% | 68 | $392.77 | |
| 94010 | <1% | 12 | $387.81 | |
| 72050 | <1% | 12 | $385.55 | |
| 86923 | <1% | 26 | $377.24 | |
| 96417 | <1% | 3,140 | $366.89 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 5,368 | $360.29 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 4,907 | $358.84 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 326 | $343.56 |
| 93226 | <1% | 15 | $339.57 | |
| 93018 | <1% | 50 | $322.69 | |
| 83516 | <1% | 45 | $307.16 | |
| 80178 | <1% | 31 | $286.76 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,870 | $285.44 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 6,262 | $264.46 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 669 | $258.34 |
| 36593 | <1% | 19 | $253.28 | |
| 82627 | <1% | 12 | $250.11 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 15,458 | $231.14 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 6,599 | $223.41 |
| J1439 | Injection, ferric carboxymaltose, 1 mg | <1% | 78 | $213.33 |
| 36600 | <1% | 3,130 | $209.73 | |
| 87521 | Neg quan hep c or qual rna | <1% | 12 | $203.24 |
| 85014 | <1% | 1,075 | $201.49 | |
| 86708 | <1% | 55 | $191.10 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 501 | $179.38 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,634 | $165.41 |
| 96521 | <1% | 189 | $146.13 | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 154 | $144.82 |
| 86308 | <1% | 66 | $143.71 | |
| 82952 | <1% | 96 | $141.43 | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 166 | $139.06 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 24,262 | $135.34 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 673 | $132.83 |
| 83002 | <1% | 12 | $132.39 | |
| 82140 | <1% | 66 | $125.13 | |
| 96411 | <1% | 1,262 | $123.26 | |
| 71101 | <1% | 27 | $120.61 | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 428 | $104.12 |
| 87075 | <1% | 299 | $99.61 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 954 | $94.15 |
| 73552 | <1% | 13 | $86.99 | |
| 85018 | <1% | 1,062 | $78.87 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 3,301 | $78.71 |
| 86003 | <1% | 13 | $73.32 | |
| J9045 | Injection, carboplatin, 50 mg | <1% | 1,038 | $72.96 |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 1,229 | $66.50 |
| J1815 | Injection, insulin, per 5 units | <1% | 3,362 | $61.33 |
| 81015 | <1% | 224 | $56.19 | |
| 88304 | <1% | 506 | $55.84 | |
| 82150 | <1% | 13 | $55.33 | |
| 87493 | <1% | 13 | $51.15 | |
| 82010 | <1% | 269 | $47.36 | |
| 83550 | <1% | 12 | $47.23 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 3,707 | $45.90 |
| 80143 | <1% | 66 | $34.34 | |
| 85046 | <1% | 12 | $32.46 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 4,572 | $28.47 |
| 82803 | <1% | 290 | $26.36 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 655 | $25.66 |
| 80179 | <1% | 65 | $17.11 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 5,271 | $16.66 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 3,156 | $12.82 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,847 | $10.78 |
| 94761 | <1% | 4,989 | $9.81 | |
| 82270 | <1% | 41 | $7.76 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 424 | $7.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 143 | $3.10 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 266 | $2.78 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 2,192 | $2.53 |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 218 | $0.00 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | 0% | 744 | $0.00 |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 82 | $0.00 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 0% | 384 | $0.00 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 0% | 1,793 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 255 | $0.00 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 406 | $0.00 |
| 72170 | 0% | 13 | $0.00 | |
| J9267 | Injection, paclitaxel, 1 mg | 0% | 629 | $0.00 |
| J7999 | Compounded drug, not otherwise classified | 0% | 152 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 111 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 27 | $0.00 |
| 82330 | 0% | 63 | $0.00 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 53 | $0.00 |
| C9463 | Injection, aprepitant, 1 mg | 0% | 36 | $0.00 |
| 82077 | 0% | 87 | $0.00 | |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 83 | $0.00 |
| 88720 | 0% | 12 | $0.00 | |
| C1781 | Mesh (implantable) | 0% | 13 | $0.00 |
| J1836 | Injection, metronidazole, 10 mg | 0% | 34 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 13,831 | $0.00 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 84 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 129 | $0.00 |
| J9190 | Injection, fluorouracil, 500 mg | 0% | 274 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 278 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 318 | $0.00 |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | 0% | 622 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 275 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 2,439 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 68 | $0.00 |
| J0688 | Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg | 0% | 78 | $0.00 |
| 87150 | 0% | 28 | $0.00 | |
| J0640 | Injection, leucovorin calcium, per 50 mg | 0% | 119 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 69 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 38 | $0.00 |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 0% | 13 | $0.00 |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 0% | 15 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 44 | $0.00 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 0% | 32 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialANDERSON, DONALD (ASSISTANT SECRETARY FOR ENROLLMENT)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.